In my last article on DexCom (NASDAQ:DXCM) back in June last year, I argued that the stock could be a potential multi-bagger. The stock was then trading just below $22. Earlier this month, DXCM created an all-time high of $49.83 before correcting ~15%. Generally it is considered that a 15% correction from the top is a buying opportunity for a stock undergoing a secular bull phase. In this article I will analyze whether investors should consider this mild correction a buying opportunity or they should stay away from DXCM after its meteoric rise over the last twelve months.
DXCM Received FDA-Clearance for G4 PLATINUM for Pediatric Use
DXCM announced last month that it has received FDA clearance for...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|